Psychopharmacology elective course summary (17/20 first session)
15 views 2 purchases
Course
Psychopharmacology
Institution
Thomas More Hogeschool (tmhs)
Complete and comprehensive summary of the psychopharmacology elective course. The summary is in English, as the course is also taught in English.
I added things that were difficult to explain in Dutch. Difficult subject with a lot of subject matter, but if you start with this summary on time, it ...
3. Influences from Psychiatry ......................................................................................................................... 17
3.1. Early pharmacotherapy (1860-1930: before WOII) ................................................................................... 17
3.1.1. Social background .............................................................................................................................. 17
3.1.2. Therapeutic options for the incurable ............................................................................................... 18
3.2. Experimenting with hallucinogenics (1880 - 1940).................................................................................... 19
3.2.1. Accidental discovery of LSD (1938) .................................................................................................... 20
3.2.2. Applications and the public of LSD (post-WO II)................................................................................ 20
3.2.3. How does LSD work and how is it related to Psychotic Episodes? .................................................... 21
3.2.4. Hallucinogenic experiments .............................................................................................................. 22
3.3. The first antidepressant (1930-1950: during WOII) ................................................................................... 22
3.3.1. Social background .............................................................................................................................. 22
3.3.2. Benzedrine®: The uplifting nasal decongestant ................................................................................ 23
3.3.3. Conquering depression during the heydays of the 20th century ...................................................... 23
3.4. The revolutionary decade (post WW II): ANTIPSYCHOTICS ....................................................................... 24
3.4.1. Social background .............................................................................................................................. 24
3.4.2. Phenothiazines (heel goed kennen) .................................................................................................. 25
3.5. The revolutionary decade (post WW II): ANTIDEPRESSANTS .................................................................... 26
3.6. The revolutionary decade: ANXIOLYTICS .................................................................................................. 27
3.7. The revolutionary decade (post WW II): ANTIMANIC DRUGS ................................................................... 27
3.8. In conclusion .............................................................................................................................................. 28
1. Key concepts of Behavioral Neuroscience .................................................................................................. 29
1.1. Anatomy & Organization of the Nervous System ...................................................................................... 30
1
, 1.1.1. Different nervous systems ................................................................................................................. 31
1.1.2. Central nervous system ..................................................................................................................... 32
1.1.3. The deep brain structures ................................................................................................................. 33
1.1.4. What are cells made of? Including neurons ...................................................................................... 33
1.2. Origin of Signal .......................................................................................................................................... 38
1.3. Neural Communication (zie gedragsneuro) ............................................................................................... 39
1.3.1. Communication within a neuron ........................................................................................................... 40
1.3.1.1. Membrane Potentials ..................................................................................................................... 40
1.3.2. Action potential (zie gedragsneuro) .................................................................................................. 43
1.4. Communication between neurons ............................................................................................................ 45
1.4.1. Synaptic communication ................................................................................................................... 45
1.5. Endocrinergic Communication ................................................................................................................... 51
1.5.1. Subtle differences .............................................................................................................................. 52
1.5.1.1. Endocrinergic neurons .................................................................................................................... 52
1.5.1.2. Endocrinergic glands (specialized structures in our body) ............................................................. 53
2. Principles of psychopharmacology: general framework ............................................................................. 55
3. Key concepts of Psychopharmacology: Pharmacokinetics .......................................................................... 57
3.1. Routes of administration ........................................................................................................................... 57
3.2. Absorption & distribution .......................................................................................................................... 62
3.2.1. Partition coefficient is too high ......................................................................................................... 64
3.2.2. Partition coefficient is moderate drug .............................................................................................. 64
3.2.3. Partition coefficient is too low........................................................................................................... 65
3.3. Depot binding (niet heel erg in detail kennen) .......................................................................................... 68
3.4. Inactivation & biotransformation .............................................................................................................. 69
3.5. Excretion .................................................................................................................................................... 72
3.6. Pharmacokinetics: summarize ................................................................................................................... 73
4. Key concepts of Psychopharmacology: Pharmacodynamics ....................................................................... 74
4.1. CNS-Behavioral Categorization of Drugs ................................................................................................... 74
4.2. From synaptic activity… ............................................................................................................................. 75
4.2.1. Drugs as ligands ................................................................................................................................. 76
4.2.3. Dynamic reactions: downregulation and upregulation ..................................................................... 81
4.3. … To behavioral effects .............................................................................................................................. 83
4.3.1. From a drug action to a drug effect ................................................................................................... 83
4.3.2. Dose Response Curves (DRCs) ........................................................................................................... 83
4.3.4. Tolerance ⬄ sensitization ................................................................................................................. 84
4.3.5. Kinetics and dynamics interact with each other ................................................................................ 85
1. Preclinical research .................................................................................................................................... 87
1.1. Animal research and ethics....................................................................................................................... 88
1.1.1. The challenge of testing with animals: .............................................................................................. 89
1.1.2. Focus on construct validity ................................................................................................................ 89
1.1.3. Other quality checks: ......................................................................................................................... 89
1.2. How do we study psychiatric disorders in rodents? ................................................................................... 90
1.3. Example of an animal model ..................................................................................................................... 90
1.4. The 3 R’ and moral principles: research with animals requires moral guidelines ...................................... 92
2
, 2. Clinical research ......................................................................................................................................... 93
2.1. Methodological issues ............................................................................................................................... 94
2.2. Post-marketing research, phase IV ............................................................................................................ 98
2.2.1. FDA/FAGG assessment ...................................................................................................................... 98
2.2.2. Increased regulations = increased costs: discussion ......................................................................... 99
2.3. INCB – International Narcotics Control Board ........................................................................................... 99
After a drug has been approved by the FDA: Phase IV ................................................................................... 102
1. Therapy (non)adherence .......................................................................................................................... 104
1.1. Defining therapy (non)adherence ............................................................................................................ 104
1.2. Factors related to therapy (non)adherence ............................................................................................. 105
1.3. societal problems related to therapy (non)adherence ............................................................................ 109
1.3.1. Social biases ..................................................................................................................................... 109
2. The case of Scott Martin: introduction + instructions ............................................................................... 111
4.1. Getting to know Scott .............................................................................................................................. 111
4.2. Treatment adherence: a new hope ......................................................................................................... 111
4.3. The short-term effects of Lithium ............................................................................................................ 111
4.4. The 6-week follow-up .............................................................................................................................. 112
4.5. Putting strain on Scott’s treatment adherence ....................................................................................... 112
4.6. Remarkable effects come in small packages ........................................................................................... 112
3. How to improve Therapy Adherence ........................................................................................................ 112
1. .................................................................................................................................................................. 114
1.1. Defining substance use disorder .............................................................................................................. 114
1.1.1 Different degrees of substance use disorder.................................................................................... 114
2. What’s in a name ..................................................................................................................................... 115
2.1. Dependency ............................................................................................................................................. 115
2.2. Addiction ................................................................................................................................................. 116
2.3. Abuse ....................................................................................................................................................... 116
2.4. Substance induced disorders or SIDs ....................................................................................................... 116
2.5. "Behavioural addictions" ......................................................................................................................... 117
3. Biopsychosocial mechanisms of SUD ........................................................................................................ 118
3.1. The mesolimbic pathway - The reward system ....................................................................................... 118
3.2. The neurobiology of tolerance and withdrawal ...................................................................................... 119
3.3. Hebbian learning ..................................................................................................................................... 120
3.4. Homeostatis and opponent Proces Theory .............................................................................................. 121
3.5. Evaluation in cravings.............................................................................................................................. 122
3.6. The social network hypothesis ................................................................................................................. 123
4. Treatment strategies of SUDs ................................................................................................................... 123
3
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through EFT, credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying this summary from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller nelethys. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy this summary for R128,21. You're not tied to anything after your purchase.
